Charles Patrick France
Affiliations: | Pharmacology | University of Texas Health Science Center at San Antonio, San Antonio, TX, United States |
Area:
Behavioral pharmacologyGoogle:
"Charles France"Mean distance: 15.11 (cluster 19) | S | N | B | C | P |
Cross-listing: Chemistry Tree
Parents
Sign in to add mentor| James H. Woods | grad student | 1985 | University of Michigan | |
| (Three-choice drug discrimination in pigeons: interactions between opioid agonists and antagonists (dependence).) | ||||
| William H. Morse | post-doc | Harvard Medical School | ||
Children
Sign in to add trainee| Michael Brandt | grad student | University of Texas Health Science Center at San Antonio | |
| Ruggero Galici | grad student | University of Texas Health Science Center at San Antonio | |
| Lisa R. Gerak | grad student | University of Texas Health Science Center at San Antonio | |
| Lance R. McMahon | grad student | University of Texas Health Science Center at San Antonio | |
| Lawrence P. Carter | grad student | 2005 | UT Health San Antonio |
| Rajkumar J. Sevak | grad student | 2006 | UT Health San Antonio |
| Michelle G. Baladi | grad student | 2011 | UT Health San Antonio |
| Jun-Xu Li | post-doc | University of Texas Health Science Center at San Antonio | |
| Stacy L. Sell | post-doc | UTMB | |
| Katherine M. Serafine | post-doc | 2012-2015 | University of Texas Health Science Center at San Antonio |
| Gregory T. Collins | research scientist | University of Texas Health Science Center at San Antonio |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| France CP, Ahern G, Averick S, et al. (2020) Countermeasures for preventing and treating opioid overdose. Clinical Pharmacology and Therapeutics |
| Mada S, Gerak LR, Soyer A, et al. (2020) Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist. Psychopharmacology |
| Minervini V, Disney A, Husbands SM, et al. (2020) Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys. Psychopharmacology |
| Maguire DR, France CP. (2020) Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures. Drug and Alcohol Dependence. 212: 108043 |
| Maguire DR, Gerak LR, Sanchez JJ, et al. (2020) Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Maguire DR, Gerak LR, Cami-Kobeci G, et al. (2019) OREX-1019: a novel treatment for opioid use disorder and relapse prevention. The Journal of Pharmacology and Experimental Therapeutics |
| Maguire DR, Minervini V, Dodda V, et al. (2019) Impact of order of fixed-ratio presentation on demand for self-administered remifentanil in male rats. Behavioural Pharmacology |
| Gerak LR, Maguire DR, France CP. (2019) Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors. Handbook of Experimental Pharmacology |
| Gerak LR, Minervini V, Latham E, et al. (2019) Methocinnamox (MCAM) produces long-lasting antagonism of the behavioral effects of µ opioid receptor agonists but not prolonged precipitated withdrawal in rats. The Journal of Pharmacology and Experimental Therapeutics |
| Collins GT, Sulima A, Rice KC, et al. (2019) Self-administration of the synthetic cathinones 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (α-PVP) in rhesus monkeys. Psychopharmacology |